Advanced

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity

Matino, D.; Lillicrap, D.; Astermark, Jan LU ; Dolan, G.; Kessler, C.; Lambert, T.; Makris, M.; O'Donnell, J.; Pipe, S. and Santagostino, E., et al. (2014) In Haemophilia 20(2). p.200-206
Abstract
The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi... (More)
The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haemophilia
volume
20
issue
2
pages
200 - 206
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000331459600026
  • scopus:84894269397
ISSN
1351-8216
DOI
10.1111/hae.12283
language
English
LU publication?
yes
id
e2b3e97e-5203-4fe5-9aa6-982df9dd5f36 (old id 4470288)
date added to LUP
2014-07-01 07:39:10
date last changed
2017-04-02 03:09:20
@article{e2b3e97e-5203-4fe5-9aa6-982df9dd5f36,
  abstract     = {The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue.},
  author       = {Matino, D. and Lillicrap, D. and Astermark, Jan and Dolan, G. and Kessler, C. and Lambert, T. and Makris, M. and O'Donnell, J. and Pipe, S. and Santagostino, E. and Saint-Remy, J. -M. and Schramm, W. and Iorio, A.},
  issn         = {1351-8216},
  language     = {eng},
  number       = {2},
  pages        = {200--206},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity},
  url          = {http://dx.doi.org/10.1111/hae.12283},
  volume       = {20},
  year         = {2014},
}